Entries |
Document | Title | Date |
20080207557 | Methods of Decreasing or Preventing Pain Using Spicamycin Derivatives - Methods of providing pain relief by administering a water-soluble derivative of spicamycin. Methods of using pain mediation agents are also provided. | 08-28-2008 |
20080249059 | Compositions and Methods for modulating Calcium Flux, Glucose Homeostasis and Apoptosis - Compositions and methods are disclosed which are effective for modulating glucose homeostasis, calcium ion flux and cell death in target cells. | 10-09-2008 |
20080269161 | Compositions and Methods Relating to Mitochondrial Hyperpolarization in Neurological Disease - Provided is a method of protecting a neuron from dysfunction induced by an HIV neurotoxin comprising contacting the cell with a therapeutically effective dose of an inhibitor of mitochondrial hyperpolarization. | 10-30-2008 |
20080280849 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents - The invention relates to a combination comprising a quinoline compound or its sail, according to general formula (I) and at least one HIV infection therapeutic agent selected from the group consisting of entry inhibitors, reverse-transcriptase inhibitors, strand-transfer inhibitors, protease inhibitors, and maturation inhibitors. Said combination has therapeutic synergy in the treatment of an HIV infection compared with the quinoline compound, or HIV infection therapeutic agent alone. | 11-13-2008 |
20080293664 | Non-nucleoside reverse transcriptase inhibitors - Compounds of formula I, wherein R | 11-27-2008 |
20090012034 | Non-Nucleoside reverse transcriptase inhibitors - Compounds of formula I, wherein R | 01-08-2009 |
20090023677 | Modulation of Telomere Length in Telomerase Positive Cells and Cancer Therapy - Induction of telomere shortening, G2 arrest and apoptosis in telomerase positive cancer cells using acyclic nucleoside analogs has been disclosed. In addition, methods for impairment or prevention of tumorigenic telomerase positive cells from having a chance to grow into a tumor and methods for promoting tumor regression (decrease in size of an established tumor) using acyclic nucleoside analogs has been disclosed. | 01-22-2009 |
20090048202 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION - An agent for inhibiting translesion DNA replication comprises a non-natural adenine ribose analog represented by those as set forth in FIG. | 02-19-2009 |
20090054369 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS - Novel compositions of silicon-containing anti-metabolite compounds, their preparation and use in methods for treating cancer are described. The silyl group confers lipophilicity that can enhance the penetration of the compounds across the gut wall, cell membranes and blood brain barrier, thus improving therapeutic properties including bioavailability, metabolism, and/or pharmacokinetics. The triorganosilyl group provides compounds having improved pharmacokinetics and anti-tumor activity. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for treatment of diseases and other maladies or conditions involving cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 02-26-2009 |
20090075930 | DEUTERIUM-ENRICHED NELARABINE - The present application describes deuterium-enriched nelarabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090099126 | Ribonucleoside Cyclic Acetal Derivatives for the Treatment of RNA-Dependent RNA Viral Infection - The present invention provides ribonucleoside 2′,3′-cyclic acetals of structural formula I which are precursors or prodrugs of inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors of inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as pre-cursors or prodrugs of inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors or prodrugs of inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such ribonucleoside 2′,3′-cyclic acetals alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the ribonucleoside 2′,3′-cyclic acetals of the present invention. | 04-16-2009 |
20090105184 | POSITRON EMISSION TOMOGRAPHY PROBES FOR IMAGING IMMUNE ACTIVATION AND SELECTED CANCERS - Compounds for use as PET probes and methods for synthesizing and using these, comprising [ | 04-23-2009 |
20090105185 | Nucleosides with anti-hepatitis B Virus activity - A method for the treatment of a host, and in particular, a human, infected with hepatitis B virus (HBV) is provided that includes administering an effective amount of a β-L-nucleotide, optionally in combination therapy with other drugs for the treatment of HBV or human immuno-deficiency virus (HIV). | 04-23-2009 |
20090118220 | SUBSTITUTED ADENINES AND THE USES THEREOF - This invention relates to compounds of Formula I: | 05-07-2009 |
20090131363 | Deuterated darunavir - This invention relates to novel compounds that are hydroxyethylamino sulfonamide derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel hydroxyethylamino sulfonamide derivatives that are derivatives of darunavir. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a human immunodeficiency virus (HIV) protease inhibitor, such as darunavir. | 05-21-2009 |
20090137520 | A1 ADENOSINE RECEPTOR AGONISTS - Disclosed are novel compounds that are A | 05-28-2009 |
20090149415 | Compounds for modulating the glycolysis enzyme complex and/or the transaminase complex - The invention relates to compounds for modulating the glycolosis enzyme complex and the transaminase complex, to pharmaceutical compositions containing said compounds, and to the uses of said compounds for the production of pharmaceutical compositions for treating different diseases. | 06-11-2009 |
20090149416 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation - Provided are cyclobutyl nucleosides and methods for their use in treatment of infections including Retroviridae (including HIV), Hepadnaviridae (including HBV), or Flaviviridae (including BVDV and HCV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans. | 06-11-2009 |
20090170803 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES - The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with an A | 07-02-2009 |
20090170804 | PIRFENIDONE/TOLL-LIKE RECEPTOR (TLR) AGONIST COMPOSITIONS AND METHODS FOR USING THEM TO STIMULATE PRODUCTION OF GRANULOCYTE COLONIZING STIMULATING FACTOR (G-CSF) - The invention disclosed herein relates to compositions and methods for treating subjects suffering from or at risk of developing neutropenia. In some embodiments, the methods comprise administering to a subject suffering from or at risk of developing neutropenia, an effective amount of pirfenidone and one or more toll-like receptor (TLR) agonists. | 07-02-2009 |
20090192119 | Inhibition of the Renin-Angiotensin System for the Treatment of Renal, Vascular and Cartilage Pathology - A method of treating a disease or condition in which up-regulating GAGs is therapeutically beneficial is disclosed. The method comprises locally administering to a subject a therapeutically effective amount of an agent capable of down-regulating activity or expression of a component of the renin-angiotensin system. | 07-30-2009 |
20090203636 | Prevention and Treatment of Cancer and Other Diseases - Nucleoside chemical compounds, which interact with specific structures of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) are disclosed. The compounds interfere with the activities of telomerase and reverse transcriptase, and are useful as antivirals, antibacterials and anticancer agents. Methods of treating or preventing cancers in patients involving administration of a therapeutically effective amount of a composition having an inhibitor or antagonist of the reverse transcriptases (RTs) expressed in cells of the patients are also disclosed. Method of using nucleoside analogs and other inhibitors of RTs in conjunction with DNA damaging agents such as genotoxic agents or radiation or photodynamic therapy or combinations these for the treatment of various cancers are also disclosed. | 08-13-2009 |
20090215712 | PYRAZOLE DERIVATIVES - This invention relates to pyrazole derivatives of formula (I) | 08-27-2009 |
20090264382 | Methods for Treating Hematopoietic Neoplasms - This invention relates to methods for treating, preventing and/or managing hematopoietic neoplasm in a subject by administering to the subject combretastatin A-4 phosphate, or a pharmaceutically acceptable salt thereof. The method may further comprise co-administering a chemotherapeutic agent. | 10-22-2009 |
20090291908 | Use of thiophoshonoformic acid and nrtis to treat viral infections - This invention provides for a method of synergistically reducing viral load in a patient infected with a virus. The method comprises the oral co-administering an amount of thiophosphonoformic acid and an amount of a nucleoside or nucleotide reverse transcriptase inhibitor in a synergistic combination. | 11-26-2009 |
20090318380 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS - Embodiments of the invention are to compounds, methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention are 2′,4′-substituted nucleoside compounds useful for the treatment of viral infections, such as HIV, HCV, and HBV infections. | 12-24-2009 |
20100056464 | COMPOUNDS, COMPOSITIONS AND METHODS OF USING SAME FOR MODULATING URIC ACID LEVELS - Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid. | 03-04-2010 |
20100069319 | Mercaptopurine derivatives and uses thereof - The invention provides novel mercaptopurine derivatives, e.g., S-allylthio-6-mercaptopurine and S-allylthio-6-mercaptopurine 9-riboside, as well as pharmaceutical compositions thereof. These compounds are highly efficient anti-proliferative agents, thus can be useful for treatment of various diseases or disorders, in particular, proliferative, inflammatory, skin and immune diseases or disorders. | 03-18-2010 |
20100075914 | METHODS FOR TREATING HERPES VIRUS INFECTIONS - The present invention relates to methods for treating, killing, and/or inhibiting the growth of Herpes viruses in human subjects comprising topically administering to a human subject in need thereof a nanoemulsion composition having antiviral properties. | 03-25-2010 |
20100093655 | USE OF RILUZOLE AND DERIVATIVES THEREOF FOR PRODUCING NEW DRUGS - The present invention relates to the use of riluzole or pharmaceutically acceptable salts of riluzole in the production of drugs for restoring and amplifying the immune function in the treatment of infectious diseases and cancers. | 04-15-2010 |
20100144663 | 2, 6-Dinitrogen-Containing Substituted Purine Derivatives, The Preparation And Uses Thereof - The present invention provides 2,6-dinitrogen-containing substituted purine compounds of formula (A) or salts or solvates thereof or the solvates of salts thereof, as well as pharmaceutical compositions containing such compounds. The compounds of the present invention have the characteristics of lower toxicity, broad anticancer spectrum, higher anticancer activity, good stability and the like. The compounds are useful for the manufacture of an antitumor medicament. The present invention also provides a process for preparing these compounds. | 06-10-2010 |
20100152126 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B - This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: | 06-17-2010 |
20100160248 | ISOTOPICALLY MODIFIED COMPOUNDS AND THEIR USE AS FOOD SUPPLEMENTS - A nutrient composition comprises an essential nutrient in which at least one exchangeable H atom is | 06-24-2010 |
20100160249 | NANOPARTICLE DERIVATIVES OF GEMCITABINE - The use of squalenic acid or a derivative thereof in formulating at least one polar active principle with a molecular weight of 100 Da or more, in the form of nanoparticles, and pharmaceutical compositions thereof. | 06-24-2010 |
20100173863 | 2-Fluoronucleosides - 2′-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: | 07-08-2010 |
20100197626 | Biomarkers for Depression and Methods Using the Same - The present invention provides various biomarkers of depression. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of depression, methods of determining predisposition to depression, methods of monitoring progression/regression of depression, methods of assessing efficacy of compositions for treating depression, methods of screening compositions for activity in modulating biomarkers of depression, methods of treating depression, as well as other methods based on biomarkers of depression. | 08-05-2010 |
20100204172 | INACTIVATORS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE - Disclosed are compounds that are AGT inactivators that include a folate residue, e.g., a compound of formula (I), wherein X | 08-12-2010 |
20100227832 | Modulation of telomere length in telomerase positive cells and cancer therapy - Induction of telomere shortening, G2 arrest and apoptosis in telomerase positive cancer cells using acyclic nucleoside analogs has been disclosed. In addition, methods for impairment or prevention of tumorigenic telomerase positive cells from having a chance to grow into a tumor and methods for promoting tumor regression (decrease in size of an established tumor) using acyclic nucleoside analogs has been disclosed. | 09-09-2010 |
20100279968 | Mutagenic Nucleoside Analogs for the Treatment of Viral Disease - The present invention relates to methods of treating viral disease using mutagenic nucleoside analogs. | 11-04-2010 |
20100279969 | AZIDO PURINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS - The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HIV, HBV, and HCV, in human patients or other animal hosts. The compounds are 3′-azido-2′,3′-dideoxy purine nucleosides or phosphonates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1 resistance mutants including HIV-1 | 11-04-2010 |
20100311681 | STABLE 6-METHOXY-2',3'-DIDEOXYGUANOSINE, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - A stable 6-methoxy-2′,3′-dideoxyguanosine comprises 6-30% water content. It is prepared by absorbing water in 6-methoxy-2′,3′-dideoxyguanosine with less than 6% water content at low temperature and certain humidity, or drying 6-methoxy-2′,3′-dideoxyguanosine with more than 30% water content. The stable 6-methoxy-2′,3′-dideoxyguanosine can be used to prepare medicament composition, and be used to manufacture pharmaceutical for fighting hepatitis B virus or HIV. | 12-09-2010 |
20110003764 | Methods for Treatment of HIV or Malaria Using Combinations of Chloroquine and Protease Inhibitors - The present invention relates to a drug combination capable of conferring therapeutic benefits in the treatment of both AIDS and malaria. In particular, it relates to a drug combination including at least one quinolinic antimalarial compound such as chloroquine or hydroxychloroquine, and at least one inhibitor of the Human Immunodeficiency Virus (HIV) protease enzyme. This drug combination is capable of inhibiting the replication of both HIV and | 01-06-2011 |
20110046082 | DEUTERIUM-ENRICHED NELARABINE - The present application describes deuterium-enriched nelarabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 02-24-2011 |
20110053883 | AGENT THAT MODULATES PHYSIOLOGICAL CONDITION OF PESTS, INVOLVED IN INSECT C-JUN AMINO-TERMINAL KINASE ACTIVITY - The present invention provides an agent that modulates physiological condition of pests, wherein the agent has an ability to modulate the activity of an insect c-Jun NH | 03-03-2011 |
20110144049 | Treating Cardiac Arrhythmias, Heart Failure, Peripheral Artery Disease and Stroke with Cyclopentyl-Triazolo-Pyrimidine or Derivative Thereof - The present invention relates to new methods for treating and/or preventing cardiac arrhythmias, heart failure, stroke and/or peripheral artery disease by administering a composition comprising triazolopyrimidine, or derivative or metabolite thereof. In particular, the present invention relates to methods for treating cardiac arrhythmias, heart failure, stroke and/or peripheral artery disease by administering CycloPentyl-TriazoloPyrimidine. | 06-16-2011 |
20110152213 | RIBOSWITCHES, METHODS FOR THEIR USE, AND COMPOSITIONS FOR USE WITH RIBOSWITCHES - It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural “riboswitches” (created by using various nucleic acid engineering strategies) can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies. In addition, the architecture of riboswitches allows actual pieces of the natural switches to be used to construct new non-immunogenic genetic control elements, for example the aptamer (molecular recognition) domain can be swapped with other non-natural aptamers (or otherwise modified) such that the new recognition domain causes genetic modulation with user-defined effector compounds. The changed switches become part of a therapy regimen—turning on, or off, or regulating protein synthesis. Newly constructed genetic regulation networks can be applied in such areas as living biosensors, metabolic engineering of organisms, and in advanced forms of gene therapy treatments. | 06-23-2011 |
20110195922 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B - This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: | 08-11-2011 |
20110195923 | Methods for Predicting the Response to Anti-Cancer Treatment with an Agonist of TLR7 or an Agonist of TLR8 - The present invention relates to methods for predicting the response to treatment with an agonist of TLR7, or an agonist of TLR8 or an anti-cancer agent for treating cancer, in particular non-small cell lung cancer comprising the step of detecting the expression of TLR7 or TLR8 in cancer cells of said patient. | 08-11-2011 |
20110207688 | HETEROCYCLIC ANTIVIRAL COMPOUNDS - The present invention relates to a method of treating an HIV-I infection with a compound according to formula I where R | 08-25-2011 |
20110218169 | Pirfenidone/Toll-Like Receptor (TLR) Agonist Compounds and Methods of Treating Neutropenia - The invention disclosed herein relates to compositions and methods for treating subjects suffering from or at risk of developing neutropenia. In some embodiments, the methods comprise administering to a subject suffering from or at risk of developing neutropenia, an effective amount of pirfenidone and one or more toll-like receptor (TLR) agonists. | 09-08-2011 |
20110230433 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER - Described herein are novel methods and compositions for treatment of cancer by increasing the mutation rate of cancer cells beyond an error threshold, over which the cancer cells are no longer viable. In particular, mutagenic compounds such as nucleoside analogs for treatment of cancer are also described herein. | 09-22-2011 |
20110237536 | Treating or Preventing Pain Using Spicamycin Derivatives - The present invention relates to the use of spicamycin derivatives for treatment and/or prevention of pain, including neuropathic pain. The invention further relates to pharmaceutical compositions of spicamycin derivatives suitable for treatment or prevention of pain. | 09-29-2011 |
20120010164 | ANTIVIRAL AGENTS - Compounds of structural formula (I): and pharmaceutically acceptable salts thereof; as defined herein, are described for use in the prevention and/or treatment of HCV infections. Novel compounds of the formula (I) and pharmaceutical formulations containing them are also described. | 01-12-2012 |
20120135950 | ANTIVIRAL TREATMENT OF LYMPHOMA AND CANCER - Compositions and methods to treat lymphoma and cancer are disclosed. In particular, the method teaches treatment of lymphoma and cancer using anti-HERV-K(HML-2) therapies. Further taught are compositions and methods for characterizing patient samples to, for example, select or identify therapeutic options or assess the impact of therapies. | 05-31-2012 |
20120165284 | PHARMACEUTICAL COMPOSITION COMPRISING A3 ADENOSINE RECEPTOR AGONIST (IB-MECA/CF-101) FOR TREATMENT OF PSORIASIS - The present invention is based on the clinical finding that twice daily administrations of 2 mg of 1-[N | 06-28-2012 |
20120232028 | Bicyclic Compound, Production and Use Thereof - The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: | 09-13-2012 |
20120270828 | QUADRUPLE THERAPY USEFUL FOR TREATING PERSONS AFFLICTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) - The present invention relates to a pharmaceutical composition for treating the human immunodeficiency virus (HIV) in a human being, comprising four active principles selected as being:
| 10-25-2012 |
20120283211 | MEDICAL IMPLANTS CONTAINING ADENOSINE RECEPTOR AGONISTS AND METHODS FOR INHIBITIING MEDICAL IMPLANT LOOSENING - The invention provides methods and compositions for reducing or inhibiting bone resorption, osteoclast differentiation and stimulation and the loosening of medical prostheses by administering a compound or agent that modulates an adenosine receptor such as the adenosine A | 11-08-2012 |
20120302518 | Polymorphic Form Of N-(S)-(3,4-Difluoro-2-(2-Fluoro-4-Iodophenylamino)-6-Methoxyphenyl)-1-(2,- 3-Dihydroxypropyl)Cyclopropane-1-Sulfonamide And Uses Thereof - Disclosed herein, in certain embodiments, is a crystalline polymorph form A of N—(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide. Further disclosed herein, in certain embodiments, are pharmaceutical compositions comprising the crystalline polymorph form A of N—(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide. | 11-29-2012 |
20120309705 | NOVEL 3'-DEOXY-3'-METHYLIDENE-BETA-L-NUCLEOSIDES - The present invention includes novel 3′-deoxy-3′-methylidene-β-L-nucleosides, pharmaceutical composition comprising such compounds, as well as the methods to treat or to prevent viral infections and in particular HBV and/or HIV infections. In accordance with the present invention, there are provided compounds represented by Formula (I), wherein B is selected from A1 and A2; | 12-06-2012 |
20120316126 | Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 12-13-2012 |
20130035306 | PROCESS FOR PREPARING PURINE NUCLEOSIDES - The present invention provides for the preparation β-adenine nucleosides by coupling an adenine derivative containing an unprotected exocyclic amino group at the C-6 position and a blocked arabinofuranosyl derivative, in the presence of a base and solvent. The present invention also provides for the stereoselective preparation of 2-deoxy-β-D-adenine nucleosides wherein a blocked 2-deoxy-α-D-arabinofuranosyl halide is coupled with the salt of an adenine derivative. The forgoing aspects of the present invention are utilized in the preparation of a clofarabine composition wherein the ratio of β to α-anomer is at least 99:1. | 02-07-2013 |
20130090299 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS - The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 04-11-2013 |
20130196940 | ANHYDROUS POLYMORPHS OF [(2R,3S,4R,5R)-5-(6-(CYCLOPENTYLAMINO)-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAH- YDROFURAN-2-YL)} METHYL NITRATE AND PROCESSES OF PREPARATION THEREOF - The present invention provides novel anhydrous polymorph forms of 2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate (Compound A). The present invention also provides processes for preparation of the anhydrous polymorphic forms of compound A. | 08-01-2013 |
20130244964 | NOVEL HIV-1 REVERSE TRANSCRIPTASE CODON DELETION AND ITS USE IN THE MANAGEMENT AND TREATMENT OF HIV INFECTIONS - The present invention provides an isolated HIV-1 mutant and isolated nucleic acid molecules comprising HIV-RT coding sequences harboring a novel mutation in the S68 codon, and in particular, deletions of the S68 codon. This novel deletion reduces the sensitivity of HIV to various nucleoside reverse transcriptase inhibitors. Methods of using this mutation for selecting effective antiretroviral agents in vitro and in vivo, methods for monitoring infection progression in HIV-infected individuals and methods for avoiding the emergence of and/or to treat individuals infected with HIV comprising mutations, including deletions, at the S68 codon of HIV-RT are provided. | 09-19-2013 |
20130244965 | ASSAYS AND METHODS FOR DETERMINING RISK OF A MACROPHAGE-MEDIATED DISEASE DEVELOPMENT IN A SUBJECT INFECTED WITH HIV - The invention is generally related to assays and methods for determining the risk of an HIV+ individual for developing a macrophage-mediated disease using measurement of soluble CD163 levels in a biological sample. The invention also provides assays and methods for monitoring efficacy of a treatment or a drug for a macrophage-mediated disease, and assays and methods for screening for agents to treat a macrophage-mediated disease in an HIV+ individual by monitoring soluble CD163 levels. | 09-19-2013 |
20130261073 | MODULATOR OF ACTIVITY OF ADENYLATE CYCLASE - The present invention provides a novel compound capable of inhibiting cardiac adenylyl cyclase. | 10-03-2013 |
20130310333 | Modulators of Histone Methyltransferase, and Methods of Use Thereof - Disclosed are compounds, pharmaceutical compositions containing the compounds, and the uses of the compounds and compositions as modulators of histone methyltransferases, and for treating diseases influenced by modulation of histone methyltransferase activity. | 11-21-2013 |
20140005136 | NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | 01-02-2014 |
20140045780 | COMPOSITIONS COMPRISING SPICAMYCIN DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to compositions comprising spicamycin derivatives, methods of making such compositions, and their use in the treatment and/or prevention of pain, including neuropathic pain. | 02-13-2014 |
20140213539 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS - Disclosed is a synthesis suitable for large scale manufacture of an A | 07-31-2014 |
20140213540 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS - 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions. | 07-31-2014 |
20140288018 | METHODS FOR PREDICTING THE RESPONSE TO ANTI-CANCER TREATMENT WITH AN AGONIST OF TLR7 OR AN AGONIST OF TLR8 - The present invention relates to methods for predicting the response to treatment with an agonist of TLR7, or an agonist of TLR8 or an anti-cancer agent for treating cancer, in particular non-small cell lung cancer comprising the step of detecting the expression of TLR7 or TLR8 in cancer cells of said patient. | 09-25-2014 |
20140296176 | COMBINATION CANCER THERAPY WITH AN HSP90 INHIBITOR AND AN ANTIMETABOLITE - The invention provides a method of treating a subject with cancer, particularly leukemia, lymphoma, solid cancer such as colorectal cancer, gastric cancer, bladder cancer, non-small cell lung cancer, and breast cancer, comprising administering to the subject a compound of formulae (I) 40 or (Ia) in combination with an antimetabolite such as methotrexate, pemetrexed, cytarabine or nelarabine, or 5-fluorouracil, or capecitabine or their derivatives. | 10-02-2014 |
20140323423 | BIOSYNCHRONOUS TRANSDERMAL DRUG DELIVERY FOR LONGEVITY, ANTI-AGING, FATIGUE MANAGEMENT, OBESITY, WEIGHT LOSS, WEIGHT MANAGEMENT, DELIVERY OF NUTRACEUTICALS, AND THE TREATMENT OF HYPERGLYCEMIA, ALZHEIMER'S DISEASE, SLEEP DISORDERS... - Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible. An automated, pre-programmable transdermal administration system is used to provide pulsed doses of medications, pharmaceuticals, hormones, neuropeptides, anorexigens, pro-drugs, stimulants, plant extracts, botanicals, nutraceuticals, cosmeceuticals, phytochemicals, phytonutrients, enzymes, antioxidants, essential oils, fatty acids, minerals, vitamins, amino acids, coenzymes, or other physiological active ingredient or precursor. The system can utilize a pump, pressurized reservoir, a system for removing depleted carrier solution, or other modulated dispensing actuator, in conjunction with porous membranes or micro-fabricated structures. | 10-30-2014 |
20140343006 | HIV Replication Inhibiting Pyrimidines - This invention concerns HIV replication inhibitors of formula | 11-20-2014 |
20140357594 | NEW COMPOUNDS - This invention relates to heteroaryl compounds, containing a purinyl moiety, that inhibit DNA methyltransferase (DNMT) activity—including DNMT1, DNMT3a, or DNMT3b—useful in the treatment of cancer and hyperproliferative diseases. | 12-04-2014 |
20140364388 | METHOD FOR INDUCING HEPATOCYTE PROLIFERATION AND USES THEREOF - The present application provides methods and compositions for inducing hepatocyte proliferation and liver regeneration, the latter being mainly dependent on hepatocyte proliferation even if all the other cell types divide to reconstitute the organ specific-lobular-architecture. The methods and compositions provided herein make use of an A | 12-11-2014 |
20150018297 | COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASES INCLUDING COMPOUND DOWNREGULATING EXPRESSION OF BACE1 PROTEINS - The present disclosure relates to a pharmaceutical composition, a health functional food composition, and a method for preventing or treating a brain disease or diabetes. The pharmaceutical composition, health functional food composition, and method includes at least one active ingredient that is chlorhexidine, thioguanosine, mebendazole, fenbendazole, colchicine, farnesol, trimethobenzamide hydrochloride, disulfuram, azathioprine, mebeverine hydrochloride, zaprinast, tosufloxacin hydrochloride, efavirenz, thiostrepton, probenecid, entacapone, harmine hydrochloride, flunisolide, thimerosal, hexestrol, sulfaquinoxaline sodium salt, monensin sodium salt, raloxifene hydrochloride, 2-chloropyrazine, or topotecan. | 01-15-2015 |
20150025031 | METABOLIC DOWNREGULATION FOR CELL SURVIVAL - The present invention provides a system and method of maintaining and/or increasing cell viability by downregulating cellular metabolic rate under hypoxic conditions, wherein the availability of adenosine or derivatives thereof in the cell is increased and/or prolonged. The present invention also relates to a system and method of prolonging the survival of implanted cells that are under hypoxic condition until host neovascularization is achieved, wherein the availability of adenosine or derivatives thereof in the cell is increased and/or prolonged. The present invention also provides a system and method of maintaining and/or increasing cell viability by downregulating cellular metabolic rate under hypoxic conditions, wherein at least one purine metabolism enzyme inhibitor is applied to the cell. | 01-22-2015 |
20150057243 | Compositions and Methods for the Inhibition of Methyltransferases - Methods and compositions disclosed herein relate to detecting, analyzing, isolating and inhibiting methyltransferases, methyltransferase substrates, S-adenosyl-methionine-binding proteins and RNA, including for the treatment of disease. | 02-26-2015 |
20150141362 | Inhibitors of Human EZH2, and Methods of Use Thereof - The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject. | 05-21-2015 |
20150297721 | COMPOSITIONS COMPRISING SPICAMYCIN DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to compositions comprising spicamycin derivatives, methods of making such compositions, and their use in the treatment and/or prevention of pain, including neuropathic pain. | 10-22-2015 |
20150299801 | Techniques for Treating Acute Lymphoblastic Leukemia (ALL) - The invention is based on the discovery of certain new somatic single nucleotide substitution mutations of NT5C2 gene variants found in some Acute Lymphoblastic Leukemia (ALL) relapse subjects. Techniques include obtaining a biological sample taken from a subject having ALL, and detecting the presence or absence in the biological sample of a biomarker selected from the group consisting of an NT5C2 gene mutation, an mRNA transcribed from the NT5C2 gene mutation, or a protein encoded by the NT5C2 gene mutation. The method also includes determining that the subject has increased resistance to treatment with 6-mercaptopurine or 6-thioguanine, if the biomarker is detected. In some embodiments, the method still further includes treating the subject with a nucleoside analog other than 6-mercaptopurine or 6-thioguanine if the biomarker is detected. | 10-22-2015 |
20160022725 | INJECTABLE FORMULATIONS FOR TREATING CANCER - The present invention provides injectable formulations of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders. | 01-28-2016 |
20160024134 | METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS - The present invention provides an efficient process for the synthesis of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also provides novel crystalline forms of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof (Form A, Form B, and Form C), characterized by a unique X-ray diffraction pattern and Differential Scanning calorimetry profile, as well as a unique crystalline structure. | 01-28-2016 |
20160068559 | Modulators of Histone Methyltransferase, and Methods of Use Thereof - Disclosed are compounds, pharmaceutical compositions containing the compounds, and the uses of the compounds and compositions as modulators of histone methyltransferases, and for treating diseases influenced by modulation of histone methyltransferase activity. | 03-10-2016 |
20160090397 | Se-Adenosyl-L-Selenohomocysteine Selenoxide As A Modulator Of Methyltransferase And Other Activities - The invention relates to a compound of the structural formula | 03-31-2016 |
20160374967 | ORGANIC THIOPHOSPHATE ANTIRETROVIRAL AGENTS - A method for the prevention or treatment of human immunodeficiency virus infection by administering an effective amount of amifostine, phosphonol, or similar compound to an individual in need is provided. | 12-29-2016 |
20190142831 | TREATMENT OF ROSACEA WITH P38 AND ERK KINASE PATHWAY INHIBITORS | 05-16-2019 |